Neurontin Fraudulent Marketing Class Action

TBS represented a national class of insurance providers alleging that in an effort to boost profits, Pfizer, Inc. and Warner-Lambert Co. sold the drug Neurontin for uses for which it was neither approved by the U.S. Food and Drug Administration nor medically effective. Pfizer Inc. agreed to pay $325 million to resolve the class’s claim that Pfizer defrauded insurers and other healthcare benefit providers by its off label marketing of Neurontin.

Case Documents

Chase - You have saved me tens of thousands of dollars over what I could have obtained had I tried to handle the matter myself. With hundreds of thousands of dollars at stake you were worth every penny of your most reasonable fee....
Stanley R. Byrd Contact Us
Kim is by far one of the BEST litigators around! You can always expect big results from him and his law firm....
Noah Wick, M.A. Contact Us
Kevin is a great fit for the issue he helped with and continues to help with. We have followed him from another firm to TBS and have worked with him for 10 years now...I appreciate Kevin and what he continues to do to assist us....
Leif Langlois Contact Us